All In Biotech

Drug Trial Radar · NCT05419492

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

113

Planned (sponsor's estimate)

Start

May 14, 2024

Primary completion

Jun 2028

Study completion Jun 2034

Sponsor

Lead sponsor
Encoded TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham delayed-treatment control study.

Conditions

  • Dravet Syndrome

Interventions

  • ETX101Drug

    ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in monthly countable seizure frequency (MCSF) between the Pre-Dosing Seizure Period and the Post-Dosing Assessment Period.Time frame: Between the Pre-Dosing Seizure Period and the Post-Dosing Assessment Period (defined as Week 5 to Week 52).

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospitals

    San Francisco, California · Recruiting

  • Colorado Children's Hospital

    Aurora, Colorado · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • NYU Langone Health

    New York, New York · Not yet recruiting

  • Duke Children's Hospital & Health Center

    Durham, North Carolina · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University (OHSU)

    Portland, Oregon · Recruiting

  • Cook Children's Medical Center

    Fort Worth, Texas · Recruiting

  • The Royal Children's Hospital

    Melbourne, Australia · Recruiting

  • Queen Elizabeth Hospital

    Glasgow, United Kingdom · Recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.